The Diabetes Report

Table of Contents

TYPE I DIABETES

• R&D Update
  • Study validates tight blood sugar control
  • Generex commences new Oral-lyn studies
  • Brain plays key role in diabetes therapy
  • Emory receives grant for advancing islet transplantation in Type I diabetes
  • Study finds more fractures and lower BMD in premenopausal females with Type I diabetes

TYPE II DIABETES

• R&D Update
  • Rosiglitazone added early to SU therapy effective in older Type II diabetes patients; combined with fenofibrate improves metabolic parameters; may improve memory in males
  • Generex' Metformin Gum shows similar PK profile to tablets
  • Hh protein shown to block fat production and produce more bone
  • CIDR to use Illumina whole-genome genotyping solutions to support study for Type II diabetes collaboration
  • deCODE discovers major genetic risk factor for Type II diabetes
  • PhytoMedical plans to accelerate development of cinnamon-derived compound for Type II diabetes
  • Extensive analysis confirms Lipitor' s safety
  • Positive results in Phase IIb dose-ranging study of MannKind' s Technosphere insulin in Type II diabetes
  • New evidence for increased CV mortality risk associated with SUs
  • Novartis to file Galvus in 2006
  • ConjuChem' s PC-DAC:Exendin-4 advancing into Phase I/II trial
  • Metaglidasen as effective as rosiglitazone and pioglitazone in preclinical study
  • Takeda' s SYR-322 in Phase III stage; ATL-962 enters Phase II studies
• Product News
  • GSK post-marketing reports warn of macular oedema with rosiglitazone products
  • Sanwa releases Seibule
  • Ajinomoto and Astellas file Fastic/Starsis sNDA for Type II diabetes
  • Ranbaxy launches Volix
• Agreement News
  • BI returns tesofensine rights to NeuroSearch

GENERAL

• R&D Update
  • UNSW produces new SC line
  • Generex granted US patent in connection with RapidMist device
  • Geron reports improved production method for hESC-derived islet cells
• Product News
  • Generex receives scheduling for Oral-lyn pre-NDS meeting
  • EC and FDA approve Exubera for treatment of Type I and II diabetes
• Agreement News
  • PS closes diabetes partnership
  • HGS receives milestone payment from GSK for GSK716155
  • Vitro and PhosphoSolutions enter SC proteomics collaboration
  • Pfizer acquires rights to Exubera from sanofi-aventis
  • ChemGenex and Merck enter diabetes agreement

RELATED COMPLICATIONS

• R&D Update
  • UVa scientists to search for new treatments for DNP
  • Ranirestat improves peripheral nerve function in DSP
  • King initiates Phase II trial evaluating MRE0094 in diabetic foot ulcers
  • Mosapride may improve appetite loss associated with diabetes
  • Corautus and CSEMC to study VEGF-2 for CLI
  • Molecular link between hyperglycaemia and retinopathy identified
  • Sangamo plans Phase II trial of SB-509 in DN
  • Discovery of glucagon secretion mechanism may lead to improved therapies for diabetics
  • Quigley' s SAB strongly supports next stage of development
  • Regranex gel confirmed as effective treatment for diabetic neuropathic foot ulcers

CONFERENCE LISTINGS

COMPANY INDEX

COMPOUND INDEX